Lip filler study shows promise for fuller lips in chinese adults

NCT ID NCT05342753

First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 31 times

Summary

This study tested the safety and effectiveness of Restylane Kysse, a hyaluronic acid gel, for lip augmentation in 22 Chinese adults. Participants received injections to improve lip fullness, and doctors measured changes using a lip fullness scale over 48 weeks. The goal was to see if the treatment provided at least a one-point improvement in lip fullness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIP AUGMENTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Galderma Research Site

    Los Angeles, California, 94538, United States

  • Galderma Research Site

    Vista, California, 92083, United States

  • Galderma Research Site

    Ardmore, Pennsylvania, 19003, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Restylane Kysse (hyaluronic acid injectable gel)

What this could lead to

If successful, this could confirm that Restylane Kysse is a safe and effective option for lip enhancement in Chinese individuals.

What could go wrong

This was a small, completed study with only 22 participants. Results may not apply to everyone, and risks like swelling or bruising are possible with any injectable filler.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.